Just before the pandemic, a research project was initiated in Tullinge in which residents were offered a place at a local work hub as an alternative to commuting to work. The hub is now seeing something of a reopening in a project aimed at increasing shared use and resource efficiency.
During the Kodkupan award evening in Flemingsberg, parents got to see the results of middle school students’ programming projects. Games and animations from the project were shown, prompting laughter and applause.
Nearly 100,000 people in Sweden suffer from Alzheimer’s. Globally, about 30 million people are thought to have the disease. There is still no cure, but research is approaching a point where new drugs may become crucial. AlzeCure is one of the pharmaceutical companies that has made the most progress.
“Cellaviva was founded by researchers from Karolinska Institutet, in the belief that stem cells will revolutionize how complex and incurable diseases are treated. We are a biobank that helps expectant parents to save stem cells from the umbilical cord at birth, in a so-called family bank. The aim is to make high-quality, potent cells available quickly, if medical needs arise. This creates treatment opportunities and expands therapy options for the whole family,”
NextCell Pharma in Flemingsberg has published extremely promising results from its clinical studies of drug candidate ProTrans for the treatment of type 1 diabetes. A study is now being carried out with the aim of examining its efficacy in children and young people.
Foundation Flemingsberg Science is to join the Swedish Incubators & Science Parks network, a collaboration that will accelerate the development of Flemingsberg’s internationally competitive innovation environment.
The “Kodkuporna” programme started in Flemingsberg in May, a project that gives children and young people the opportunity to try their hand at programming. Students from KTH and Södertörn University mentor middle school students from Vistaskolan in play-based learning.
Developing Advanced Therapy Medicinal Products (ATMPs) is a growing field. Karolinska Institute and Karolinska University Hospital have unique facilities and expertise in this field.
The pre-GMP laboratory at Karolinska Institutet gives companies the opportunity to develop products, drugs and treatments. It is hoped for an increased interest from the industry to cooperate. Professor Matti Sällberg, head of the pre GMP unit, talks more about how this can be helpful early in the development.
Flemingsberg Science Foundation has recently developed a new strategic direction with clear goals for the coming years. The focus of the plan is on co-ordinating and strengthening efforts to attract more companies to Flemingsberg.